Abstract: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors. In this issue, Barrios et al present a study in which 120 treatment-naive patients with metastatic RCC were enrolled in a single-arm, open-label, phase 2 trial of continuous once-daily sunitinib. This study and other data provide insight into optimal dosing of sunitinib in metastatic RCC.
Publication Year: 2012
Publication Date: 2012-03-01
Language: en
Type: paratext
Indexed In: ['crossref']
Access and Citation
Cited By Count: 4
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot